Compare SHASUN PHARMA with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA WOCKHARDT SHASUN PHARMA/
WOCKHARDT
 
P/E (TTM) x 123.9 -19.5 - View Chart
P/BV x 8.5 1.0 830.6% View Chart
Dividend Yield % 0.2 0.0 6,209.6%  

Financials

 SHASUN PHARMA   WOCKHARDT
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
WOCKHARDT
Mar-18
SHASUN PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs941,012 9.3%   
Low Rs46532 8.6%   
Sales per share (Unadj.) Rs214.2355.9 60.2%  
Earnings per share (Unadj.) Rs5.3-60.3 -8.9%  
Cash flow per share (Unadj.) Rs15.8-46.8 -33.8%  
Dividends per share (Unadj.) Rs1.000.01 10,000.0%  
Dividend yield (eoy) %1.40 110,407.7%  
Book value per share (Unadj.) Rs53.3257.8 20.7%  
Shares outstanding (eoy) m56.62110.63 51.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.2 15.0%   
Avg P/E ratio x13.1-12.8 -102.3%  
P/CF ratio (eoy) x4.4-16.5 -26.8%  
Price / Book Value ratio x1.33.0 43.8%  
Dividend payout %18.70 -112,965.4%   
Avg Mkt Cap Rs m3,95885,379 4.6%   
No. of employees `000NA6.3 0.0%   
Total wages/salary Rs m2,1649,371 23.1%   
Avg. sales/employee Rs ThNM6,295.0-  
Avg. wages/employee Rs ThNM1,498.3-  
Avg. net profit/employee Rs ThNM-1,066.3-  
INCOME DATA
Net Sales Rs m12,12739,369 30.8%  
Other income Rs m2291,202 19.1%   
Total revenues Rs m12,35640,571 30.5%   
Gross profit Rs m1,00918 5,513.9%  
Depreciation Rs m5941,495 39.7%   
Interest Rs m4152,555 16.2%   
Profit before tax Rs m230-2,830 -8.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m-73257 -28.3%   
Profit after tax Rs m302-6,669 -4.5%  
Gross profit margin %8.30 17,900.6%  
Effective tax rate %-31.7-9.1 348.6%   
Net profit margin %2.5-16.9 -14.7%  
BALANCE SHEET DATA
Current assets Rs m6,88433,796 20.4%   
Current liabilities Rs m8,45626,917 31.4%   
Net working cap to sales %-13.017.5 -74.2%  
Current ratio x0.81.3 64.8%  
Inventory Days Days6279 77.7%  
Debtors Days Days10889 120.5%  
Net fixed assets Rs m4,97039,664 12.5%   
Share capital Rs m113553 20.5%   
"Free" reserves Rs m2,87527,968 10.3%   
Net worth Rs m3,02028,522 10.6%   
Long term debt Rs m1,81721,731 8.4%   
Total assets Rs m13,34781,620 16.4%  
Interest coverage x1.6-0.1 -1,444.7%   
Debt to equity ratio x0.60.8 79.0%  
Sales to assets ratio x0.90.5 188.4%   
Return on assets %5.4-5.0 -106.6%  
Return on equity %10.0-23.4 -42.8%  
Return on capital %13.3-7.7 -173.6%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,8439,807 59.6%   
Fx outflow Rs m2,1731,789 121.5%   
Net fx Rs m3,6698,019 45.8%   
CASH FLOW
From Operations Rs m398684 58.1%  
From Investments Rs m-1,6356,302 -25.9%  
From Financial Activity Rs m1,309-7,695 -17.0%  
Net Cashflow Rs m71-664 -10.7%  

Share Holding

Indian Promoters % 39.2 74.5 52.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 2.3 156.5%  
FIIs % 17.6 7.7 228.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 39.6 15.4 257.1%  
Shareholders   20,750 67,757 30.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  AJANTA PHARMA  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS